4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Predictors for the utilization of social service counseling by prostate cancer patients

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Social service counseling (SSC) is an important instrument to support cancer patients, for example, regarding legal support, or rehabilitation. Several countries have established on-site SSC in routine care. Previous analyses have shown that SSC utilization varies across cancer centers. This analysis investigates patient and center-level predictors that explain variations in SSC utilization between centers.

          Methods

          Logistic multilevel analysis was performed with data from 19,865 prostate cancer patients from 102 prostate cancer centers in Germany and Switzerland. Data was collected within an observational study between July 2016 and June 2020 using survey (online and paper) and tumor documentation.

          Results

          The intraclass correlation coefficient for the null model implies that 51% of variance in SSC utilization is attributable to the center a patient is treated in. Patients aged 80 years and older, with higher education, private insurance, without comorbidities, localized intermediate risk, and undergoing androgen deprivation therapy before study inclusion were less likely to utilize SSC. Undergoing primary radiotherapy, active surveillance, or watchful waiting as compared to prostatectomy was associated with a lower likelihood of SSC utilization. Significant negative predictors at the center level were university hospital, center’s location in Switzerland, and a short period of certification.

          Conclusion

          The results show that patient and center characteristics contribute to explaining the variance in SSC utilization in prostate cancer centers to a large extent. The findings may indicate different organizational processes in the countries included and barriers in the sectoral structure of the healthcare system. In-depth analyses of processes within cancer centers may provide further insights into the reasons for variance in SSC utilization.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

          Europe contains 9% of the world population but has a 25% share of the global cancer burden. Up-to-date cancer statistics in Europe are key to cancer planning. Cancer incidence and mortality estimates for 25 major cancers are presented for the 40 countries in the four United Nations-defined areas of Europe and for Europe and the European Union (EU-28) for 2018.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

            Background Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on patient-reported outcomes. Methods We compared patient-reported outcomes among 1643 men in the Prostate Testing for Cancer and Treatment (ProtecT) trial who completed questionnaires before diagnosis, at 6 and 12 months after randomization, and annually thereafter. Patients completed validated measures that assessed urinary, bowel, and sexual function and specific effects on quality of life, anxiety and depression, and general health. Cancer-related quality of life was assessed at 5 years. Complete 6-year data were analyzed according to the intention-to-treat principle. Results The rate of questionnaire completion during follow-up was higher than 85% for most measures. Of the three treatments, prostatectomy had the greatest negative effect on sexual function and urinary continence, and although there was some recovery, these outcomes remained worse in the prostatectomy group than in the other groups throughout the trial. The negative effect of radiotherapy on sexual function was greatest at 6 months, but sexual function then recovered somewhat and was stable thereafter; radiotherapy had little effect on urinary continence. Sexual and urinary function declined gradually in the active-monitoring group. Bowel function was worse in the radiotherapy group at 6 months than in the other groups but then recovered somewhat, except for the increasing frequency of bloody stools; bowel function was unchanged in the other groups. Urinary voiding and nocturia were worse in the radiotherapy group at 6 months but then mostly recovered and were similar to the other groups after 12 months. Effects on quality of life mirrored the reported changes in function. No significant differences were observed among the groups in measures of anxiety, depression, or general health-related or cancer-related quality of life. Conclusions In this analysis of patient-reported outcomes after treatment for localized prostate cancer, patterns of severity, recovery, and decline in urinary, bowel, and sexual function and associated quality of life differed among the three groups. (Funded by the U.K. National Institute for Health Research Health Technology Assessment Program; ProtecT Current Controlled Trials number, ISRCTN20141297 ; ClinicalTrials.gov number, NCT02044172 .).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Prostate cancer and supportive care: a systematic review and qualitative synthesis of men's experiences and unmet needs

              Prostate cancer is the second most common cancer in men worldwide, accounting for an estimated 1.1 million new cases diagnosed in 2012 (www.globocan.iarc.fr). Currently, there is a lack of specific guidance on supportive care for men with prostate cancer. This article describes a qualitative systematic review and synthesis examining men's experience of and need for supportive care. Seven databases were searched; 20 journal articles were identified and critically appraised. A thematic synthesis was conducted in which descriptive themes were drawn out of the data. These were peer support, support from partner, online support, cancer specialist nurse support, self‐care, communication with health professionals, unmet needs (emotional support, information needs, support for treatment‐induced side effects of incontinence and erectile dysfunction) and men's suggestions for improved delivery of supportive care. This was followed by the development of overarching analytic themes which were: uncertainty, reframing, and the timing of receiving treatment, information and support. Our results show that the most valued form of support men experienced following diagnosis was one‐to‐one peer support and support from partners. This review highlights the need for improved access to cancer specialist nurses throughout the care pathway, individually tailored supportive care and psychosexual support for treatment side effects.
                Bookmark

                Author and article information

                Contributors
                breidenbach@krebsgesellschaft.de
                lena.ansmann@uni-oldenburg.de
                sibert@krebsgesellschaft.de
                wesselmann@krebsgesellschaft.de
                s.dieng@onkozert.de
                guenther@carl-soft.de
                g-feick@gmx.de
                cindy.stoklossa@charite.de
                Anne.Taubert@med.uni-heidelberg.de
                amanda.pomery@movember.com
                b.beyer@uke.de
                Andreas.Blana@klinikum-fuerth.de
                marko.brock@proselis.de
                Florian.Distler@klinikum-nuernberg.de
                Michael.Enge@sanktgeorg.de
                a.gaber@ctk.de
                christian.gilfrich@klinikum-straubing.de
                Andreas.Hinkel@franziskus.de
                Bjoern.Kaftan@klinikum-lueneburg.de
                t.knoll@klinikverbund-suedwest.de
                frank.kunath@uk-erlangen.de
                Simba-Joshua.Oostdam@krh.eu
                peters.inga@mh-hannover.de
                polat_b@ukw.de
                v.schrodi@klinikum-braunschweig.de
                friedemann.zengerling@uniklinik-ulm.de
                kowalski@krebsgesellschaft.de
                Journal
                Support Care Cancer
                Support Care Cancer
                Supportive Care in Cancer
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0941-4355
                1433-7339
                4 November 2021
                : 1-13
                Affiliations
                [1 ]GRID grid.489540.4, ISNI 0000 0001 0656 7508, German Cancer Society, ; Berlin, Germany
                [2 ]GRID grid.5560.6, ISNI 0000 0001 1009 3608, Carl von Ossietzky Universität Oldenburg, ; Oldenburg, Germany
                [3 ]OnkoZert GmbH, Neu-Ulm, Germany
                [4 ]Bundesverband Prostatakrebs Selbsthilfe e. V., Bonn, Germany
                [5 ]Deutsche Vereinigung für Soziale Arbeit im Gesundheitswesen e. V., Berlin, Germany
                [6 ]Arbeitsgemeinschaft Soziale Arbeit in der Onkologie, Berlin, Germany
                [7 ]GRID grid.480919.d, ISNI 0000 0004 1791 7018, Movember Foundation, ; Melbourne, Australia
                [8 ]GRID grid.412315.0, Martini-Klinik, , Prostate Cancer Center Hamburg, ; Hamburg, Germany
                [9 ]GRID grid.473621.5, ISNI 0000 0001 2072 3087, Klinik für Urologie und Kinderurologie, ; Klinikum Fürth, Fürth, Germany
                [10 ]Department of Urology, Stiftungsklinikum Proselis, Recklinghausen, Germany
                [11 ]GRID grid.419835.2, ISNI 0000 0001 0729 8880, Urologische Klinik der Universitätsklinik der Paracelsus Medizinischen Privatuniversität am Klinikum Nürnberg, ; Nürnberg, Germany
                [12 ]Klinik für Urologie und Andrologie, Klinikum St. Georg, Leipzig, Germany
                [13 ]GRID grid.460801.b, ISNI 0000 0004 0558 2150, Carl-Thiem-Klinikum Cottbus, ; Cottbus, Germany
                [14 ]GRID grid.416619.d, ISNI 0000 0004 0636 2627, Klinikum St. Elisabeth Straubing, ; Straubing, Germany
                [15 ]GRID grid.415033.0, ISNI 0000 0004 0558 1086, Klinik für Urologie, , Franziskus Hospital Bielefeld, ; Bielefeld, Germany
                [16 ]GRID grid.416312.3, Urologische Klinik, Städtisches Klinikum Lüneburg, ; Lüneburg, Germany
                [17 ]Department of Urology, Klinikum Sindelfingen-Boeblingen, Sindelfingen, Germany
                [18 ]GRID grid.411668.c, ISNI 0000 0000 9935 6525, Department of Urology, , University Hospital Erlangen, ; Erlangen, Germany
                [19 ]Klinikum Siloah Hannover, Hannover, Germany
                [20 ]GRID grid.10423.34, ISNI 0000 0000 9529 9877, Clinic for Urology and Urologic Oncology, Hannover Medical School, ; Hannover, Germany
                [21 ]GRID grid.8379.5, ISNI 0000 0001 1958 8658, Department of Radiation Oncology, , University of Würzburg, ; Würzburg, Germany
                [22 ]GRID grid.419806.2, ISNI 0000 0004 0558 1406, Department of Urology, , Academic Hospital Braunschweig, ; Braunschweig, Germany
                [23 ]GRID grid.410712.1, Department of Urology, , Ulm University Hospital, ; Ulm, Germany
                Author information
                http://orcid.org/0000-0002-1357-472X
                Article
                6620
                10.1007/s00520-021-06620-z
                8568309
                34738162
                32119390-4ff5-4092-b13d-038f1a10bd1b
                © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 10 May 2021
                : 8 October 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100008719, Movember Foundation;
                Categories
                Original Article

                Oncology & Radiotherapy
                prostate cancer,psychosocial needs,social work,oncology,supportive care
                Oncology & Radiotherapy
                prostate cancer, psychosocial needs, social work, oncology, supportive care

                Comments

                Comment on this article